Status: Recruiting
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
The aim of this research study is to evaluate the efficacy of Elotuzumab and Iberdomide therapy post-Idecabtagene Vicleucel in participants with relapsed and refractory multiple myeloma. The names of the study drugs involved in this study are: * Iberdomide (a type of cereblon E3 ligase modulator) * Elotuzumab (a type of monoclonal antibody) * Dexamethasone (a type of steroid)
Participants needed: 49
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Omar Nadeem, MDUpdated: Dec 11, 2025Locations: 3
Eligibility criteria
Previously diagnosed with MM based on standard IMWG criteria [+18]
Prior exposure to Iberdomide [+27]